Migraine in Children: Acute & Preventive Treatment Options
TL;DR
- Ibuprofen (7.5–10 mg/kg) is first-line acute migraine treatment in children, supported by AAN/AHS guidelines; acetaminophen is an alternative.
- Rizatriptan is FDA-approved from age 6, almotriptan and zolmitriptan nasal spray from age 12 — triptans should be dosed early in the attack.
- The landmark CHAMP trial found neither amitriptyline nor topiramate outperformed placebo for pediatric migraine prevention, though all groups improved substantially with lifestyle modifications.
- Lifestyle counseling — regular sleep, meals, hydration, and stress management — is the foundation of every pediatric migraine plan.
- Refer urgently for new-onset headache with neurological signs, thunderclap onset, or headache waking the child from sleep.
Understanding Migraine in Children and Adolescents
Migraine is the most common primary headache disorder in the pediatric population. Epidemiological data suggest a prevalence of approximately 3% in children aged 3–7 years, rising to 8–23% by mid-adolescence. Before puberty, boys and girls are affected roughly equally; after menarche, the female-to-male ratio shifts toward the 3:1 pattern seen in adults (AAN/AHS 2019 practice guideline update).
Migraine treatment in children differs from adult management in several important ways. Attacks tend to be shorter (sometimes lasting only 1–2 hours), bilateral rather than unilateral, and more frequently accompanied by prominent gastrointestinal symptoms — nausea, vomiting, and abdominal pain — than in adults. The International Classification of Headache Disorders, 3rd edition (ICHD-3), permits a minimum attack duration of 2 hours in patients under 18, compared with 4 hours in adults.
The pathophysiology involves cortical spreading depolarization (the likely substrate of aura), activation of the trigeminovascular system, and release of calcitonin gene-related peptide (CGRP) and other vasoactive neuropeptides. These mechanisms are the same targets exploited by both older and emerging therapies.
Acute Treatment: Evidence and Recommendations
The goal of acute therapy is complete freedom from pain and associated symptoms within 2 hours, with the child able to return to normal activities. The AAN/AHS practice guideline and NICE CG150 both recommend early analgesic use — ideally within 30 minutes of onset — combined with rest in a quiet, dark room.
First-Line: Simple Analgesics
Ibuprofen is the best-studied acute treatment for migraine in children. A Cochrane systematic review (Richer et al., 2016) found that ibuprofen was significantly more effective than placebo for pain freedom at 2 hours, with a number needed to treat (NNT) of approximately 4. Ibuprofen migraine child dosing follows standard weight-based recommendations of 7.5–10 mg/kg per dose (maximum 400 mg), given as early as possible.
Acetaminophen (paracetamol) at 15 mg/kg (maximum 1 g) is an alternative, though the evidence favoring it over placebo is less robust than for ibuprofen. It is a reasonable first choice when NSAIDs are contraindicated — for example, in children with a history of peptic ulcer disease or renal impairment.
Naproxen sodium (5–7 mg/kg, max 500 mg) is sometimes used, particularly in adolescents, and is available in a fixed-dose combination with sumatriptan.
Clinical pearl: Encourage families to administer the analgesic at the first sign of headache, not after pain is fully established. Delayed dosing is the single most common reason for treatment failure in pediatric migraine.
Second-Line: Triptans
Triptans are selective 5-HT1B/1D receptor agonists that act on the trigeminovascular system to abort migraine. Triptans for kids have been studied extensively over the past two decades, and several now carry regulatory approval for pediatric use.
| Triptan | Formulation | Minimum Age (FDA) | Pediatric Dose |
|---|---|---|---|
| rizatriptan (Maxalt) | ODT, tablet | 6 years | 5 mg (<40 kg), 10 mg (≥40 kg) |
| almotriptan (Axert) | tablet | 12 years | 6.25–12.5 mg |
| zolmitriptan (Zomig) | nasal spray | 12 years | 2.5–5 mg nasal spray |
| sumatriptan + naproxen (Treximet) | tablet | 12 years | 10/60 mg or 85/500 mg |
| sumatriptan (Imitrex) | nasal spray | Not FDA-approved <18; EMA approved ≥12 in some regions | 10–20 mg nasal spray |
Rizatriptan has the strongest pediatric evidence base and is the only triptan FDA-approved down to age 6. The orally disintegrating tablet (ODT) formulation is practical for children with nausea who may not tolerate swallowing a conventional tablet.
Nasal spray formulations of sumatriptan and zolmitriptan offer an alternative delivery route, particularly useful when vomiting limits oral absorption. The EMA has approved sumatriptan nasal spray 10 mg for adolescents aged ≥12 in several European markets.
Triptans should not be used more than 9 days per month, to reduce the risk of medication-overuse headache. They are contraindicated in hemiplegic migraine, basilar-type migraine, and uncontrolled hypertension.
Antiemetics and Adjuncts
When nausea or vomiting is prominent, an antiemetic may be added:
- Ondansetron 0.15 mg/kg IV/PO (max 4 mg) — widely used in pediatric emergency departments.
- Prochlorperazine 0.15 mg/kg IV (max 10 mg) — has direct anti-migraine properties beyond antiemesis; monitor for dystonia.
- Metoclopramide — generally avoided in young children due to higher risk of extrapyramidal side effects.
In emergency department settings, IV ketorolac (0.5 mg/kg, max 30 mg) and IV prochlorperazine with diphenhydramine (to prevent akathisia) are commonly used rescue combinations.
Preventive Treatment: Who Needs It and What Works
Indications for Preventive Therapy
AAP and AAN/AHS guidance recommends considering pediatric migraine prevention when:
- Attacks occur ≥4 days per month (some experts use ≥6 days/month as a threshold)
- Attacks are prolonged, disabling, or poorly responsive to acute therapy
- There is significant school absenteeism or functional impairment
- Acute medication use exceeds 2 days per week, raising concern for medication-overuse headache
The CHAMP Trial: A Paradigm Shift
The Childhood and Adolescent Migraine Prevention (CHAMP) trial, published in the New England Journal of Medicine (Powers et al., 2017), was a landmark multicenter, double-blind, placebo-controlled study comparing amitriptyline (1 mg/kg/day), topiramate (2 mg/kg/day), and placebo in 328 children and adolescents aged 8–17 years.
Key findings:
- Neither amitriptyline nor topiramate was superior to placebo in reducing headache frequency at 24 weeks.
- All three groups experienced a ≥50% reduction in headache days — a substantial placebo/regression-to-the-mean effect.
- Both active drugs produced significantly more adverse effects than placebo (cognitive symptoms with topiramate; fatigue and dry mouth with amitriptyline).
- Lifestyle modifications — including headache hygiene education, regular sleep, adequate hydration, consistent meals, and moderate exercise — were administered to all participants and likely contributed to improvement across all arms.
The CHAMP trial fundamentally shifted clinical practice. Lifestyle counseling is now considered the cornerstone of pediatric migraine prevention, with pharmacotherapy reserved for children who remain significantly disabled despite non-pharmacological measures.
Pharmacological Preventive Options
Despite the CHAMP trial results, medications are still used in practice when disability persists. The evidence base is summarized below:
| Medication | Typical Dose | Evidence Level | Key Adverse Effects |
|---|---|---|---|
| amitriptyline | 0.25–1 mg/kg/day at bedtime (max 50 mg) | CHAMP: not superior to placebo; moderate-quality RCTs | Sedation, weight gain, dry mouth, QTc prolongation |
| topiramate (Topamax) | 1–3 mg/kg/day in 2 divided doses | CHAMP: not superior to placebo; some positive earlier RCTs | Cognitive dulling ("dopamax"), weight loss, paresthesias, nephrolithiasis |
| propranolol | 1–4 mg/kg/day in 2–3 divided doses (max 120 mg) | Limited pediatric RCT data; AAP lists as option | Bradycardia, hypotension, exercise intolerance, bronchospasm |
| cyproheptadine | 0.25–0.5 mg/kg/day (typically 2–4 mg BID) | Expert consensus, uncontrolled studies; often used in younger children (<6 years) | Sedation, appetite stimulation, weight gain |
| flunarizine | 5–10 mg at bedtime | Positive RCT data (not available in the United States) | Weight gain, sedation, depression (rare) |
| valproate/divalproex | 15–45 mg/kg/day | Some RCT support; FDA black-box warning for teratogenicity | Hepatotoxicity, pancreatitis, weight gain, teratogenicity — avoid in females of reproductive potential |
Amitriptyline for migraine in children remains one of the most commonly prescribed preventives despite the CHAMP trial findings, partly because clinicians observe individual benefit and because the drug may help comorbid anxiety, insomnia, or functional abdominal pain. Start at 0.25 mg/kg at bedtime and titrate slowly over 4–8 weeks. An ECG should be obtained at baseline and after dose increases to monitor for QTc prolongation.
Topiramate may be considered in adolescents where weight gain from other agents is undesirable. Cognitive side effects (word-finding difficulty, slowed processing speed) can significantly impact school performance — discuss this explicitly with families.
Propranolol is sometimes used in children with comorbid performance anxiety or tremor. It is contraindicated in asthma and must be tapered, not stopped abruptly.
Emerging Therapies: CGRP-Targeted Agents
Monoclonal antibodies targeting CGRP or its receptor — erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality) — have transformed adult migraine prevention. Pediatric data are still limited:
- Erenumab has been studied in an open-label pediatric trial showing reductions in monthly migraine days, but no large placebo-controlled RCT has been completed in patients under 18.
- Galcanezumab was studied in a phase 3 pediatric trial (REBUILD-1) that did not meet its primary efficacy endpoint, though post-hoc analyses suggested possible benefit in certain subgroups.
At this time, CGRP-targeted therapies are not approved for patients under 18 years of age by either the FDA or EMA. Their use in adolescents is strictly off-label and typically reserved for refractory cases managed in specialized headache centers.
Non-Pharmacological Approaches
The CHAMP trial underscored what headache specialists have long emphasized: lifestyle modification is not merely adjunctive — it is foundational.
Lifestyle Modifications (Headache Hygiene)
- Sleep: Consistent bedtime and wake time, aiming for age-appropriate sleep duration (9–12 hours for ages 6–12; 8–10 hours for adolescents, per AAP recommendations).
- Hydration: Adequate daily fluid intake (approximately 6–8 glasses of water).
- Meals: Regular, balanced meals — skipping breakfast is a common trigger.
- Screen time: Prolonged screen use, particularly in low-light conditions, is a frequently reported trigger.
- Physical activity: Regular moderate exercise (30–60 minutes most days) has been associated with reduced headache frequency.
- Caffeine: Discourage regular caffeine use in children; counsel adolescents about energy drinks.
Cognitive Behavioral Therapy (CBT)
CBT has the strongest evidence of any non-pharmacological intervention for pediatric migraine. The Powers et al. (2013) trial demonstrated that CBT combined with amitriptyline was superior to headache education plus amitriptyline in reducing headache days and migraine-related disability. CBT teaches relaxation techniques, biofeedback, cognitive restructuring, and activity pacing.
Nutraceuticals
Some families prefer a "natural" approach. Options with at least limited evidence include:
- Riboflavin (vitamin B2): 200–400 mg/day — generally well tolerated; evidence is modest but favorable.
- Magnesium oxide: 9 mg/kg/day in divided doses — may benefit children with low serum magnesium.
- Coenzyme Q10: 1–3 mg/kg/day — small open-label studies suggest possible benefit.
Butterbur (Petasites hybridus) was previously recommended by some guidelines but is no longer endorsed due to hepatotoxicity concerns with preparations not certified free of pyrrolizidine alkaloids.
Side Effects and Monitoring
Monitoring Schedule for Common Preventives
All preventive medications should be trialed for 8–12 weeks at adequate dose before assessing efficacy. A headache diary is essential for objective tracking.
- Amitriptyline: Baseline and follow-up ECG (QTc), weight, mood assessment. Watch for suicidal ideation (FDA black-box warning for all antidepressants in patients under 25).
- Topiramate: Baseline and periodic serum bicarbonate (risk of metabolic acidosis), renal function, intraocular pressure if visual symptoms arise. Monitor cognitive function and school performance.
- Propranolol: Baseline heart rate and blood pressure. Monitor exercise tolerance, especially in young athletes.
- Valproate: Baseline and periodic CBC, liver function tests, amylase/lipase. Pregnancy test in post-menarchal females — valproate is absolutely contraindicated in pregnancy (FDA Category X).
Contraindications and Key Drug Interactions
| Medication | Major Contraindications | Important Interactions |
|---|---|---|
| Ibuprofen | Active peptic ulcer, severe renal impairment, aspirin-exacerbated respiratory disease | Lithium (↑ levels), methotrexate (↑ toxicity), anticoagulants (↑ bleeding risk) |
| Triptans (all) | Hemiplegic/basilar migraine, uncontrolled hypertension, ischemic heart disease, concurrent MAOIs or ergotamines | SSRIs/SNRIs (theoretical serotonin syndrome risk — FDA 2006 alert, though clinical risk appears low) |
| Amitriptyline | Acute MI recovery, concurrent MAOI use, known QTc prolongation, narrow-angle glaucoma | CYP2D6 inhibitors (fluoxetine, paroxetine ↑ TCA levels), tramadol (seizure risk), other QTc-prolonging agents |
| Topiramate | Metabolic acidosis, nephrolithiasis (relative), hepatic failure | Valproate (↑ hyperammonemia risk), combined oral contraceptives (reduced efficacy at doses ≥200 mg/day), carbonic anhydrase inhibitors |
| Propranolol | Asthma/reactive airway disease, sinus bradycardia, decompensated heart failure, pheochromocytoma (without alpha-blockade) | Verapamil/diltiazem (↑ bradycardia), insulin (masks hypoglycemic symptoms), CYP1A2/2D6 substrates |
Special Populations
Children Under 6 Years
Migraine can occur in preschool-aged children, though diagnosis is often delayed. Cyproheptadine is commonly used as a first-line preventive in this age group based on expert consensus, as it is well tolerated and doubles as an appetite stimulant in children with poor oral intake. Acute treatment relies on ibuprofen or acetaminophen; no triptan is approved below age 6.
Adolescent Females
In adolescent girls, menstrual migraine may emerge post-menarche. Short-term perimenstrual prophylaxis with naproxen sodium (starting 2 days before expected menses, continued through day 3 of menstruation) or a triptan can be effective. Hormonal strategies (extended-cycle oral contraceptives) may be considered in consultation with gynecology, though estrogen-containing contraceptives are contraindicated in migraine with aura due to increased stroke risk (ACOG Practice Bulletin).
Children with Comorbid Conditions
- Epilepsy: Topiramate or valproate may serve dual purposes.
- Depression/anxiety: Amitriptyline or venlafaxine may address both conditions, but requires close monitoring for suicidal ideation.
- Obesity: Topiramate (associated with weight loss) may be preferred over amitriptyline or cyproheptadine (both associated with weight gain).
- Asthma: Avoid propranolol; prefer amitriptyline or topiramate.
Red Flags: When to Seek Urgent Medical Attention
Parents and caregivers should be counseled to seek immediate medical evaluation if the child experiences:
- Thunderclap headache — sudden onset reaching maximum intensity within seconds (rule out subarachnoid hemorrhage)
- Headache with fever, stiff neck, and photophobia — concern for meningitis
- New neurological deficits — weakness, visual loss, ataxia, seizures, or altered consciousness
- Headache waking the child from sleep consistently, or morning headache with vomiting — concern for raised intracranial pressure
- Progressive worsening over days to weeks without remission
- Headache following head trauma, particularly with vomiting or confusion
- New headache in a child under 3 years — primary migraine is uncommon at this age; secondary causes must be excluded
- Personality or behavioral changes accompanying new headache pattern
Any of these features warrants urgent neuroimaging (typically MRI with and without gadolinium) and specialist referral.
Frequently Asked Questions
Q: Is ibuprofen safe for my child's migraine? A: Yes. Ibuprofen is the most evidence-supported acute migraine treatment in children when used at appropriate weight-based doses (7.5–10 mg/kg, maximum 400 mg per dose). It should be given early in the attack, ideally within 30 minutes of headache onset. Avoid use more than 2–3 days per week on an ongoing basis to prevent medication-overuse headache.
Q: At what age can a child take a triptan? A: Rizatriptan (Maxalt) is FDA-approved from age 6. Almotriptan, zolmitriptan nasal spray, and the sumatriptan/naproxen combination are approved from age 12. Your prescriber may use certain triptans off-label in younger children under close supervision.
Q: What did the CHAMP trial show about migraine prevention in children? A: The CHAMP trial (2017) compared amitriptyline, topiramate, and placebo in 328 children aged 8–17. Neither medication was more effective than placebo at reducing headache days, though all groups improved significantly. The trial reinforced that lifestyle modifications — regular sleep, meals, hydration, and exercise — are the foundation of prevention.
Q: Should my child take a daily medication to prevent migraines? A: Daily preventive medication is typically considered when migraines occur 4 or more days per month, cause significant disability, or respond poorly to acute treatment. Given the CHAMP trial findings, most specialists now prioritize lifestyle modifications and cognitive behavioral therapy first, reserving medications for children who remain significantly impaired.
Q: Are the new CGRP medications (Aimovig, Ajovy) available for children? A: Not yet. CGRP-targeting monoclonal antibodies are not currently approved for patients under 18 years of age. Pediatric clinical trials are ongoing, but results have been mixed. Some headache specialists may prescribe them off-label for adolescents with refractory migraine after exhausting other options.
Q: Can lifestyle changes alone be enough to control my child's migraines? A: For many children, yes. The CHAMP trial demonstrated that all participants — including those taking placebo — experienced substantial improvement when structured lifestyle counseling was provided. Consistent sleep schedules, adequate hydration, regular meals, physical activity, and stress management can meaningfully reduce migraine frequency and severity.
Q: Is amitriptyline safe for children? A: Amitriptyline is one of the most commonly prescribed pediatric migraine preventives and has decades of use in children. However, it carries a black-box warning for suicidal ideation in patients under 25 and can cause sedation, weight gain, and QTc prolongation. An ECG is recommended before starting and after dose adjustments. Close follow-up is essential.
Q: My child gets migraines around their period. Is there a specific treatment? A: Menstrual migraine in adolescent girls can be managed with short-term perimenstrual prophylaxis — typically naproxen sodium or a triptan started 1–2 days before expected menses and continued for 5–7 days. Extended-cycle oral contraceptives are another option but are contraindicated in migraine with aura due to increased stroke risk. Discuss options with your child's pediatrician or gynecologist.
References
-
Lewis DW, Ashwal S, Dahl G, et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents. Neurology. 2004;63(12):2215-2224. PMID: 15623677
-
Powers SW, Coffey CS, Chamberlin LA, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2017;376(2):115-124. PMID: 27788026
-
Richer L, Billinghurst L, Linsdell MA, et al. Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database Syst Rev. 2016;(4):CD005220. cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005220.pub2
-
Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: pharmacologic treatment for pediatric migraine prevention. Neurology. 2019;93(11):500-509. PMID: 31413171
-
NICE. Headaches in over 12s: diagnosis and management. Clinical guideline CG150. 2021. nice.org.uk/guidance/cg150
-
Powers SW, Kashikar-Zuck SM, Allen JR, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. JAMA. 2013;310(24):2622-2630. PMID: 24368463
-
FDA. Label: Maxalt (rizatriptan benzoate). 2023. accessdata.fda.gov/drugsatfda_docs/label
-
Hershey AD, Powers SW, Coffey CS, et al. Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine. Headache. 2013;53(5):799-816. PMID: 23594025
-
Orr SL, Friedman BW, Christie S, et al. Management of adults with acute migraine in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. Headache. 2016;56(6):911-940. PMID: 27300483
-
El-Chammas K, Keez J, Gelfand AA, et al. Pediatric migraine: an update. Curr Opin Pediatr. 2019;31(6):733-740. PMID: 31693588
About the Author
Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with over 15 years of experience in evidence-based medication therapy management. He has worked in both hospital and community pharmacy settings, with a particular interest in neurological and pediatric pharmacotherapy. Dr. Ozarchuk contributes to PillsCard.com as a medical writer and clinical reviewer, translating complex pharmaceutical evidence into practical guidance for patients, caregivers, and healthcare professionals.
Medical Disclaimer
This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Migraine management in children should always be supervised by a qualified healthcare provider who can assess the individual patient's history, comorbidities, and response to therapy. Never start, stop, or change a child's medication without consulting their pediatrician or specialist. If your child is experiencing a medical emergency, call emergency services immediately. PillsCard.com and the author assume no liability for actions taken based on the information provided herein.